KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Net Margin (2018 - 2025)

Castle Biosciences' Net Margin history spans 7 years, with the latest figure at 2.69% for Q4 2025.

  • For Q4 2025, Net Margin fell 1380.0% year-over-year to 2.69%; the TTM value through Dec 2025 reached 7.02%, down 1251.0%, while the annual FY2025 figure was 7.02%, 1251.0% down from the prior year.
  • Net Margin for Q4 2025 was 2.69% at Castle Biosciences, down from 0.6% in the prior quarter.
  • Across five years, Net Margin topped out at 11.11% in Q4 2024 and bottomed at 91.7% in Q1 2022.
  • The 5-year median for Net Margin is 15.0% (2021), against an average of 24.75%.
  • The largest annual shift saw Net Margin crashed -7294bps in 2022 before it surged 6600bps in 2024.
  • A 5-year view of Net Margin shows it stood at 53.44% in 2021, then dropped by -1bps to 53.78% in 2022, then surged by 93bps to 3.9% in 2023, then surged by 385bps to 11.11% in 2024, then plummeted by -124bps to 2.69% in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Net Margin are 2.69% (Q4 2025), 0.6% (Q3 2025), and 5.26% (Q2 2025).